Descripción de la experiencia de un programa de Profilaxis preexposición (PrEP) a VIH en Medellín, Colombia

Contenido principal del artículo

Juan Carlos Cataño-Correa
Paula Andrea Montoya-Flórez
Jaiberth Antonio Cardona-Arias

Resumen

Objetivo: describir la experiencia de un programa de profilaxis preexposición para VIH (PrEP) en Medellín. Métodos: estudio de una cohorte retrospectiva. El programa tuvo tres fases: talleres de motivación frente al VIH y su prevención, inclusión de participantes y evaluación de desenlaces clínicos y determinantes socioeconómicos de la adherencia. Resultados: se incluyeron 50 hombres que tiene sexo con hombres y 2 mujeres trans; 79% (n=41) con nacionalidad colombiana. Al ingreso 10% presentó sífilis latente indeterminada. No se presentaron casos de VIH, 48% completó el seguimiento, se registraron leves efectos secundarios relacionados a la PrEP que no llevaron al abandono del programa. Los factores económicos fueron la causa más frecuente de abandono. Conclusión: la PrEP es efectiva y segura, los determinantes económicos son el principal factor explicativo de la adherencia. Es importante incluir la PrEP para grupos clave en los planes de salud, y ajustar el programa a la realidad socioeconómica de cada población.

Detalles del artículo

Sección
Articulos Originales

Citas

McCormack S, Dunn DT, Desai M, Dolling D, Gafos M, Gilson R, et al.Preexposure prophylaxis to prevent the acquisition of HIV-1 infection(PROUD): Effectiveness results from the pilot phase of a pragmatic openlabel randomised trial. Lancet (London, England). 2016;387(10013):53-60.DOI: 10.1016/S0140- 6736(15)00056-2.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al.New Engl J Med. 2010;2010:2587-99.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. Ondemand preexposure prophylaxis in men at high risk for HIV-1 infection.N Engl J Med. 2015;373:2237-46, DOI: 10.1056/NEJMoa1506273. https://doi.org/10.1056/NEJMoa1506273

Baeten JM, Donnell D, Ndase P, Schwart K, Soto-Torres LE, Govender V,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410, http://dx.doi.org/10.1056/nejmoa1108524

Riddell J 4th, Amico KR, Mayer KH. HIV Preexposure Prophylaxis: A Review. JAMA. 2018 Mar 27;319(12):1261-1268. doi: 10.1001/ https://doi.org/10.1001/jama.2018.1917jama.2018.191

CDC Statement on FDA Approval of Drug for HIV Prevention.[Consulta 13 agosto 2022]. Disponible en: https://www-cdc-gov.sire.ub.edu/nchhstp/newsroom/2012/fda-approvesdrugstatement.html

UN Joint Programme on HIV/AIDS (UNAIDS) to help end the AIDS epidemic. United Nations. 2014. Disponible en: https://www.unaids.org/es/pre-exposure-prophylaxis

Ministerio de Salud y Protección Social, Empresa Nacional Promotora del Desarrollo Territorial e Instituto de Evaluación Tecnológica en Salud. Guía de Práctica Clínica basada en la evidencia científica para la atención de la infección por VIH/SIDA en personas adultas, gestantes y adolescentes. Versión para profesionales de salud. Bogotá D.C. Colombia; 2021. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/gpc-vih-adultos-version-profesionales-salud.pdf

Ministerio de salud y protección social de Colombia. Resolución 2292 de diciembre de 2021. https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%202292%20de%202021.pdf

Sánchez-Rubio Ferrández J, Martínez Sesmero JM, Navarro Aznárez H, Fernández Espínola S, Escobar Rodríguez I, Ventura Cerdá JM. Perceptions about HIV pre-exposure prophylaxis among healthcare professionals in Spain (PERPPRES Study). Farm Hosp. 2016 Jul 1; 40(4):287-301. DOI: https://doi.org/10.7399/fh.2016.40.4.10489. PMID:27571497

Yoong D, Naccarato M, Sharma M, Wilton J, Senn H, Tan DH. Preparing for pre- exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis. Int J STD AIDS. 2016 Jul; 27(8):608-16. DOI: https://doi. https://doi.org/10.1177/0956462415589896org/10.1177/0956462415589896.

Krakower DS, Mayer KH. The role of healthcare providers in the roll out of preexposure prophylaxis. Curr Opin HIV AIDS. 2016 Jan; 11(1):41-8 https://doi.org/10.1097/COH.0000000000000206 DOI: https://doi.org/10.1097/COH.0000000000000206 https://doi.org/10.1097/COH.0000000000000206

Krakower DS, Mayer KH. Engaging healthcare providers to implement HIV pre- exposure prophylaxis. Curr Opin HIV AIDS. 2012 Nov; 7(6):593-9.https://doi.org/10.1097/COH.0b013e3283590446 DOI: https://doi.org/10.1097/COH.0b013e3283590446 https://doi.org/10.1097/COH.0b013e3283590446

Ravasi G, Grinsztejn B, Baruch R, Guanira JV, Luque R, Cáceres CF, et al. Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America. Journal of the International AIDS Society. International AIDS Society. 2016; 19: 21113. Available from: http://doi.https://doi.org/10.7448/IAS.19.7.21113wiley.com/10.7448/IAS.19.7.21113

Pan American Health Organization and Joint United Nations Programme on HIV/AIDS (PAHO/UNAIDS). HIV prevention Spotlight: : An Analysis from the Perspective of the Health Sector in Latin America and the Caribbean, PAHO, UNAIDS. PAHO. 2017; 1:1-7. Available from: https://iris.paho.org/handle/10665.2/34381

Blair KJ, Segura ER, Garner A, Lai J, Ritterbusch A, Leon-Giraldo S, et al. Pre- exposure prophylaxis awareness, use, and intention to use in a regional sample of Latin American geosocial networking application users in 2018-2019. Int J STD AIDS. 2021 Nov;32(13):1261-1267. doi: https://doi.org/10.1177/0956462421103461810.1177/09564624211034618 https://doi.org/10.1177/09564624211034618

Cáceres CF. HIV among gay and other men who have sex with men in Latin America and the Caribbean: A hidden epidemic? 2002; 16: AIDS https://doi.org/10.1097/00002030-200212003-000052002 Dec;16 Suppl 3:S23-33. doi: https://doi.org/10.1097/00002030-200212003-00005

UNAIDS. AIDSinfo | UNAIDS. Disponible en: http://aidsinfo.unaids.org/

AVERT. HIV and AIDS in Latin America regional overview. 2015. Disponible en: https://www.avert.org/professionals/hiv-around-world/latin-america/overview#footnote65_jpc5hcg

Guarín Téllez NE, Moreno Calderón JA, Muñoz-Galindo IM, Augusto Díaz Rojas J, Arévalo Roa HO. Cost-Effectiveness of a Care Program for HIV/ AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide. Value Health Reg Issues. 2016 Dec;11:1-8. doi:10.1016/j.vhri.2015.11.001. Epub 2016 Feb 10. PMID: https://doi.org/10.1016/j.vhri.2015.11.00127986193.

Martínez-Cajas J, Alvarado-Llano B, Martínez-Buitrago E, Torres-Isasiga J, Arrivillaga M, Camargo P, et al. HIV care providers familiarity, concerns, and attitudes about HIV PrEP in Colombia: insights from the PrEP-Col-Study, AIDS Care. 2022, DOI:10.1080/09540121.2022.2029813 https://doi.org/10.1080/09540121.2022.2029813

Martinez-Cajas JL, Torres J, Mueses HF, Plazas PC, Arrivillaga M, Gomez SA, et al. Applying implementation science frameworks to identify factors that influence the intention of healthcare providers to offer PrEP care and advocate for PrEP in HIV clinics in Colombia: a cross-sectional study.Implement Sci Commun. 2022 Mar 16;3(1):31. DOI:10.1186/s43058-022-00278-2.

Mueses-Marín HF, Alvarado-Llano B, Torres-Isasiga J, Camargo-Plazas P, Bolívar-Rocha MC, Galindo-Orrego X, et al. Scales to Assess Knowledge, Motivation, and Self-Efficacy for HIV PrEP in Colombian MSM: PrEP-COL Study. AIDS Res Treat. 2021 Sep 7;2021:4789971. DOI:10.1155/2021/4789971. https://doi.org/10.1155/2021/4789971

Marcus JL, Volk JE, Pinder J, Liu AY, Bacon O, Hare CB, et al. Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. Curr HIV/AIDS Rep. 2016 Apr 1; 13(2):116-24.https://doi.org/10.1007/s11904-016-0308-x

Torres TS, Luz PM, De Boni RB, de Vasconcellos MTL, Hoagland B, Garner A, et al. Factors associated with PrEP awareness according to age and willingness to use HIV prevention technologies: the 2017 online survey among MSM in Brazil. AIDS Care. 2019 Oct;31(10):1193-1202. Doi https://doi.org/10.1080/09540121.2019.161966510.1080/09540121.2019.1619665. https://doi.org/10.1080/09540121.2019.1619665

Cardona-Arias JA, Higuita-Gutiérrez LF, Cataño-Correa JC. Prevalencia de infección por Treponema pallidum en individuos atendidos en un centro especializado de Medellín, Colombia. Rev. Fac. Nac. Salud Pública. 2022;40(1):e343212. doi: https://doi.org/10.17533/udea.rfnsp.e343212 https://doi.org/10.17533/udea.rfnsp.e343212

Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, et al. POWER Study Team. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. 2022 Jul;25(7):e25962. doi:10.1002/jia2.25962.https://doi.org/10.1002/jia2.25962

Pagkas-Bather J, Khosropour CM, Golden MR, Thibault C, Dombrowski JC. Population-Level Effectiveness of HIV Pre-exposure Prophylaxis Among MSM and Transgender Persons With Bacterial Sexually Transmitted Infections. J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):769-775. doi: https://doi.org/10.1097/QAI.000000000000264610.1097/QAI.0000000000002646 https://doi.org/10.1097/QAI.0000000000002646

Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN.Pre- Exposure Prophylaxis for HIV Prevention: Safety Concerns. Drug Saf. 2017 Apr;40(4):273-283. doi: 10.1007/s40264-017-0505-6 https://doi.org/10.1007/s40264-017-0505-6

Mugwanya KK, Baeten JM. Safety of oral tenofovir disoproxil fumaratebased pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf. 2016;15(2):265-73. doi: 10.1517/14740338.2016.1128412. https://doi.org/10.1517/14740338.2016.1128412

Cardona-Arias JA, Cataño Correa JC, Higuita-Gutiérrez LF. HIV prevalence and associated factors in key groups and general population treated at a health care institution in Colombia in 2019: A Cross-Sectional Study.HIV AIDS (Auckl). 2020;12:381-391. doi: 10.2147/HIV.S259792. https://doi.org/10.2147/HIV.S259792